World Health Organization site
Skip Navigation Links

Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 14 July 2014
Main ID:  NCT00878189
Date of registration: 06/04/2009
Primary sponsor: Pfizer
Public title: A Trial In Patients With Advanced Cancer And Leukemia
Scientific title: A Phase 1 Trial Of PF-03084014 In Patients With Advanced Solid Tumor Malignancy And T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Date of first enrolment: June 2009
Target sample size: 72
Recruitment status: Active, not recruiting
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with advanced cancer that is resistant to standard therapy or for which no
standard therapy is available

- Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to
standard therapy or for which no standard therapy is available

- Men and women >16 years old

Exclusion Criteria:

- Prior treatment with a gamma secretase inhibitor for treatment of cancer

- Patients taking Tamoxifen

- Patients with active graft versus host disease

- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
related illness

- Patients who are pregnant or breast feeding

- Patients with clinical evidence of central nervous system disease

Age minimum: 16 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Neoplasms by Histologic Type
Drug: PF-03084014
Primary Outcome(s)
Number of participants with Dose-limiting toxicities (DLT) [Time Frame: 28 days]
Overall safety profile characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities. [Time Frame: 2 years]
Secondary Outcome(s)
Changes in NICD levels and expression levels of Notch1 target genes [Time Frame: 28 days]
Concentrations of PF 03084014 and dexamethasone at selected timepoints [Time Frame: 2 years]
Objective tumor response, overall response rate, time to tumor progression, progression free survival, and duration of response [Time Frame: 2 years]
QTc interval [Time Frame: 2 years]
Serum pharmacokinetic parameters of PF-03084014 [Time Frame: 2 years]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history